Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 97
CROI Program Committee Chair Welcome to Monday
Landon Myer
University of Cape Town, Cape Town, South Africa
from CROI 2024 on March 4, 2024 8:30 AM-9:30 AM
What's New in HIV Vaccines: Vaccine-Induced Immune Responses   (ABSTRACT 16)
Juliana M. McElrath
Fred Hutchison Cancer Center, Seattle, WA, USA
Elizabeth Connick
University of Arizona, Tucson, AZ, USA
from CROI 2024 on March 4, 2024 8:30 AM-9:30 AM
Shall We Reach Human Papillomavirus Elimination in the Face of Inequity?   (ABSTRACT 17)
Nelly R. Mugo
Kenya Medical Research Institute, Nairobi, Kenya
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
from CROI 2024 on March 4, 2024 8:30 AM-9:30 AM
INTRODUCTIONS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1   (ABSTRACT 115)
Russ P. Carstens
Merck & Co., Inc.
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Antiviral Activity, Safety, and Pharmacokinetics of GS-1720: A Novel Weekly Oral InSTI   (ABSTRACT 116)
Carl J. Fichtenbaum
University of Cincinnati, Cincinnati, OH, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
VH3810109 (N6LS) in Adults With HIV-1 Who Are ART-Naive-: Phase IIa BANNER Efficacy Data   (ABSTRACT 117)
Jan Losos
ViiV Healthcare, Research Triangle Park, NC, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236   (ABSTRACT 118)
Athe Tsibris
Brigham and Women's Hospital, Boston, MA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
INTRODUCTIONS (Part 2)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial   (ABSTRACT 119)
Babafemi Taiwo
Northwestern University, Chicago, IL, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Lenacapavir Plus bNAbs for People With HIV and Sensitivity to Either Teropavimab or Zinlirvimab   (ABSTRACT 120)
Joseph J. Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies   (ABSTRACT 121)
Boris D. Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Randomized Trial of Cabotegravir and Rilpivirine Long-Acting in Africa (CARES): Week 48 Results   (ABSTRACT 122)
Nicholas Paton
London School of Hygiene & Tropical Medicine, London, UK
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 2)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
INTRODUCTIONS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Phase I Safety, Tolerability and Pharmacokinetics of Tenofovir Alafenamide Implants in African Women   (ABSTRACT 123)
Tanuja N. Gengiah
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Final Results of ANRS 174 DOXYVAC: A Randomized Trial to Prevent STI in MSM on PrEP   (ABSTRACT 124)
Jean-Michel G. Molina
University of Paris-Est, Paris, France
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Sustained Reduction of Bacterial STIs During the DoxyPEP Study Open-Label Extension   (ABSTRACT 125)
Annie Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Doxycycline PEP: High Uptake and Significant Decline in STIs After Clinical Implementation   (ABSTRACT 126)
Hyman M. Scott
San Francisco Department of Public Health, San Francisco, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Doxy-PEP Associated With Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco   (ABSTRACT 127)
Madeline Sankaran
San Francisco Department of Public Health, San Francisco, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Site-Based HIV Testing Assay Performance for Cabotegravir and TDF-FTC PrEP Failure in HPTN 083   (ABSTRACT 128)
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV   (ABSTRACT 129)
Gillian Gillespie
Merck & Co., Inc.,
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval   (ABSTRACT 130)
Kelong Han
GSK
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083   (ABSTRACT 131)
Meredith Clement
Louisiana State University, New Orleans, LA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 2)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
INTRODUCTIONS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Safety Profile and Immunogenicity of a Phase I Clinical Trial Using Germline-Targeting Trimer GT1.1   (ABSTRACT 100)
Karlijn van der Straten
Academic Medical Center, Amsterdam, Netherlands
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Vaccine Combining Slow-Delivery and Follicle-Targeting Improve Humoral and Germinal Center Responses   (ABSTRACT 101)
Y. Jason Zhang
Massachusetts Institute of Technology, Cambridge, MA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Multi-Specificity Is a Common Trait of HIV-1 Broad Neutralizing Capacity   (ABSTRACT 102)
Alexandra Trkola
University of Zurich, Zurich, Switzerland
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
CD4 Binding Site Glycan-Deficient SHIVs Elicit Broadly Neutralizing Antibodies in Rhesus Macaques   (ABSTRACT 103)
Daniel J. Morris
University of Pennsylvania, Philadelphia, PA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
INTRODUCTIONS (Part 2)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
MHC-E Presentation Mediates SIV-Specific NK Cell Responses in SIV-Infected Rhesus Macaques   (ABSTRACT 104)
Philippe Rascle
Duke University, Durham, NC, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
[18F]F-AraG PET Imaging Reveals Unique Tissue T-Cell Activation Patterns Across HIV Infection States   (ABSTRACT 105)
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI   (ABSTRACT 106)
Preethi Krishnan
AbbVie, Inc, North Chicago, IL, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Live Single-Cycle SARS-CoV-2 Vaccine Elicits High Protection and Sterilizing Immunity   (ABSTRACT 107)
Fabian Otte
University of Basel, Basel, Switzerland
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 2)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
INTRODUCTIONS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Assessing the Contribution of Glial Activation to Cognitive Control and Declarative Memory in PWH   (ABSTRACT 109)
Leah H. Rubin
The Johns Hopkins University, Baltimore, MD, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Associations Between Depressive Symptom Severity and Incident Stroke Among People With HIV   (ABSTRACT 110)
Jimmy Ma
University of Washington, Seattle, WA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection   (ABSTRACT 111)
Meg Wilson
University of California San Francisco, San Francisco, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation   (ABSTRACT 112)
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
INTRODUCTIONS (Part 2)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
HIV Transcription Persists in the Brain of People With HIV and Viral Suppression   (ABSTRACT 113)
Melissa J. Churchill
RMIT University, Melbourne, Australia
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH   (ABSTRACT 114)
Shelli Farhadian
Yale University, New Haven, CT, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Mini-Lecture on HIV Persistence in the CNS: Considerations for Current Cure Strategies   (ABSTRACT 108)
Sharon R. Lewin
University of Melbourne, Melbourne, Australia
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 2)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 97